2022 Annual Impact Report
Our mission.
Alliance for Cancer Gene Therapy, Inc. (ACGT) funds innovative scientists working to harness the power of cell and gene therapy to transform how cancer is treated and to drive momentum toward a cure. 100% of all public donations directly support research and programs.
Our commitment.
ACGT supports high-risk, high-reward scientific research into the causes, treatment and prevention of cancer using the body’s own cells and genes as medicine. By accelerating this research, ACGT is developing cancer therapies that are significantly more effective and less toxic than current cancer treatments such as chemotherapy and radiation.
Bringing the world closer to a cure for all cancers. 31.5 million dollars awarded to groundbreaking research. 63 research fellows and collaborations supported. 36 of the top medical institutions funded.
4
Letter
from the CEO.
2022 symbolizes another year of pivotal and decisive progress for Alliance for Cancer Gene Therapy and the field of cancer cell and gene therapy as a whole. We‘ve seen advances in every sector, reflecting how our work and mission truly requires collaboration and alliances to accomplish!
ACGT Research Fellows have made crucial steps forward in their work thanks to ongoing grant funding from ACGT. Many of their developing strategies are either in clinical studies involving cancer patients or moving potentially curative therapies closer to the clinical setting.
There have been key approvals from the U.S. Food and Drug Administration for the use of cell and gene therapies in blood cancers. A couple of these authorizations from the FDA give patients with resistant blood cancers earlier access to CAR T-cell therapies, of which there are now six approved for diseases such as leukemia, lymphoma and myeloma.
Our cutting-edge collaboration with the Cancer Research Institute and Parker Institute for Cancer Immunotherapy reached Year 2. This partnership focuses exclusively on the deadly brain cancer called glioblastoma and is focused on analyzing hundreds of tissue samples to gain a first-of-its-kind cellular-level understanding of how glioblastoma forms, grows and responds to different therapies in children and adults.
This year also saw the beginning of an ACGT partnership with Chardan Capital Markets, LLC, an independent, full-service, global investment bank focused on bringing disruptive innovation to corporate and institutional clients. The partnership’s goal is to identify and financially support innovative cancer cell and gene therapy companies. In May, ACGT and Chardan began hosting a series of workshops showcasing young companies intending to make life-saving progress through high-risk, high-reward therapies or technologies that other investors might hesitate to consider.
Most recently, ACGT issued a Request for Applications for the next round of ACGT Research Fellow grants. The 2022 ACGT Investigator Awards have inspired forward-thinking scientists from many of the top cancer centers and research institutions to submit project proposals for ACGT grant funding consideration, and we are excited to award the next research grants later this calendar year. The award is for those conducting cell and gene therapy research in solid tumors with preference given to mechanistic studies that promote validation of therapeutic efficacy and help develop IND-enabling proposals.
Our progress touches every part of cell and gene therapy development: ongoing and future research projects, approvals of therapies for patient use, cutting-edge collaborations and potential investments in companies with bold ambitions that match the mission of ACGT. All of this has been made possible because of the generous donations we received this year and every year.
Our mission has never wavered. We fund innovative scientists and biotech companies working to harness the power of cell and gene therapy to transform cancer treatment and drive momentum toward a cure. This mission requires an alliance of committed supporters – ACGT Research Fellows, ACGT Scientific Advisory Council, ACGT partners and you, our donors – and meeting our mission begins with your generosity.
ACGT has never been stronger and we look forward to the coming months and years as we see these meaningful advancements continue – thanks to your support.
If you’d like to talk about how you can further impact the field of cancer cell and gene therapy, please let us know. Call me at (203) 358-5055 or email me at khoneycutt@acgtfoundation.org. Thank you again for being a part of our alliance.
With warmest regards,
Kevin Honeycutt CEO & President
1
Current ACGT grants underway.
Joseph Fraietta, PhD
University of Pennsylvania Perelman School of Medicine
Dr. Fraietta is working with his colleague, Naomi Haas, MD, on “Metabolic Reprogramming of the CAR T Cell Epigenome.” The two researchers aim to supply CAR T cells with the nutrients and energy to overcome a hostile tumor microenvironment in prostate cancer, which is diagnosed in more than 150,000 people in the United States each year.
Stephen Gottschalk, MD
St. Jude Children’s Research Hospital
Dr. Gottschalk is working to develop an effective CAR T-cell therapy for pediatric sarcoma cancers in his research program titled “ECM-targeted T-cell therapy.” Sarcoma is a group of cancers that starts in the bones and soft tissues, which connect and support other body structures. Dr. Gottschalk is exploring whether giving T cells two protein targets provides more specific direction for finding sarcoma cells and other solid tumors. This ACGT research grant is funded in part by Wendy Walk, a non-profit organization that raises awareness and funding for sarcoma research.
Dr. Chen is developing a new gene therapy approach called MAEGI that elicits a potent and specific immune response based on the unique genetic composition of a patient’s tumor to fight cancer in an individualized manner. He aims to activate the expression of specific genes in cancer tumors that can then be more easily identified and targeted by the immune system.
Dr. Chen is developing MAEGI gene therapy for pancreatic cancer and other solid tumors.
Matthias Stephan, MD, PhD Fred Hutchinson Cancer Research Center
Dr. Stephan received a grant in 2018 for his research “Preventing Cancer Vaccine Failure via Nanoparticle-Mediated TCR Programming.” Dr. Stephan’s goal is to boost the effectiveness of therapeutic cancer vaccines by giving patients the cancerspecific T cells they need to make vaccines work. His proposed method includes injecting a robust delivery system of nanoparticles that carry cancer vaccine-specific T-cell receptor genes along with a vaccine designed to trigger the patient’s immune system to fight a patient’s tumor.
Sidi Chen, PhD
Yale University School of Medicine
Dr. Chen received a three-year grant in 2020 for his research project “Initial Development of a Novel CRISPRa-Based Immune Gene Therapy of Pancreatic Ductal Adenocarcinoma.”
Brian Brown, PhD Icahn School of Medicine at Mount Sinai Hospital
Dr. Brown’s research project
“Targeting Macrophages to Turn Tumors Hot and Enhance Cancer Immunotherapy” focuses on lung cancer, the third most common cancer in the world. This ACGT research grant is funded in part this year by Swim Across America Fairfield County, which raises money to benefit ACGT. Dr. Brown is exploring ways to change “cold” tumors that shut out immune cells to “hot” tumors that immune cells can infiltrate and attack. To do this, Dr. Brown’s approach focuses on eliminating or controlling macrophages, a part of the immune system that has a function in protecting us from infections. Tumors can reprogram macrophages to suppress other
2
cells of the immune system, which benefits the tumor by preventing killer immune cells from entering the tumor and killing the cancer cells.
What Is...
What is cancer cell and gene therapy?
Cell and gene therapy is an emerging field of cancer treatment designed to harness the power of the immune system to target cancer cells. The immune system has certain cells –such as T cells, natural killer cells and dendritic cells – that help protect the body from cancer and other diseases. These cells sometimes need help finding and attacking tumors, which is what cell and gene therapies can do. Using cell and gene therapy, scientists can alter the genetics of a patient’s own immune system’s cancer-fighting cells to make them more capable of killing disease.
While CAR T cells bind directly to the cancer cells with the protein, engineered T cell receptors search for them through the major histocompatibility complex (MHC), which is a network of genes that present evidence of healthy and cancerous proteins to the T cells.
What is oncolytic virus therapy?
Amer Zureikat, MD, FACS University of Pittsburgh Medical Center
Dr. Zureikat is researching the effectiveness of “TumorInfiltrating Gamma-Delta T Cells for Pancreatic Cancer Treatment.” Dr. Zureikat believes most types of T cells require a working major histocompatability complex (MHC) (or tissue compatibility) to recognize cancer cells as dangerous. Because cancer can negatively affect the MHC and make it less effective in collaborating with T cells, Dr. Zureikat is exploring the cell and gene therapy potential of gammadelta T cells, which don’t require MHC to identify cancer cells.
What is CAR T-cell therapy?
CAR T-cell therapy is the most advanced type of cancer cell and gene therapy with six approved products currently available to patients. CAR T-cell therapy involves removing a patient’s T cells and adding a gene that gives them a powerful new protein receptor called a chimeric antigen receptor (CAR). This protein receptor teaches the T cells to look specifically for cancer cells expressing a specific protein. The engineered cells are then infused back into the patient’s body where they multiply to form an army of superpowered anti-cancer immune cells.
What are T cells?
T cells are one of the primary defenders of the human body. T cells are a type of white blood cell called lymphocytes. There are two types of T cells: cytotoxic T cells and helper T cells. Cytotoxic T cells are on the front lines of fighting cancer and other diseases. T cells can be used by doctors and researchers to develop cell and gene therapies, such as CAR T-cell therapy.
What is T-cell receptor therapy?
T-cell receptor therapy (TCR) involves engineering T cells with specific protein receptors that help the T cells look for cancer. This type of cell and gene therapy is similar to CAR T-cell therapy. Both add a protein receptor to the cells to train them to look for a protein linked to a patient’s cancer, but the mechanisms for how they find the cancerous proteins are different.
Oncolytic virus therapy is a novel cancer therapy that uses engineered viruses to break apart cancer cells. Scientists engineer the viruses by directing them to invade tumor cells. By breaking apart the cancer cells, an oncolytic virus also releases proteins that are fingerprint evidence for the immune system. Oncolytic viruses can also be transporters, or “vectors,” for other types of cell and gene therapies, and can deliver the treatment into the tumor microenvironment for a faster immune response.
Which types of cancer can cell and gene therapies treat?
The U.S. FDA has approved six CAR T-cell therapies for blood cancers like leukemia, lymphoma and myeloma. In recent years, ACGT has prioritized funding for cell and gene therapies that address solid tumors. This initiative is now advancing to clinical trials where new therapies are put to the test with patients. Current ACGT Research Fellows are focused on pancreatic cancer, lung cancer, ovarian cancer, prostate cancer and sarcomas; however, their cell and gene therapies also have potential for many other hard-to-treat solid tumors, such as glioblastoma.
What is glioblastoma?
Glioblastoma is a fast-growing type of brain cancer with poor survival rates for most patients. Approximately 12,000 people in the U.S. are diagnosed with glioblastoma each year. Due to the limited number of therapies for this cancer and the discouraging prognosis most patients face, developing cell and gene therapies for this cancer is a priority of ACGT. Two types of cell and gene therapies showing promise for glioblastoma are CAR T-cell therapy and oncolytic virus therapy.
3
3
Two academic grants recently completed.
Two ACGT Research Fellows reach conclusion of their ACGT grants. Two innovative scientists recently reached the conclusion of their multi-year research grants from ACGT. These grants were awarded as a result of a competitive funding process and ACGT’s belief in the scientists’ proposals and their potential to advance the field of cancer cell and gene therapy.
We are pleased to see ACGT’s funding – built on the power of scientific rigor and supported by donor contributions – was put to good use in gaining a deeper understanding of how cell and gene therapy can transform the immune system into a cancer-fighting force.
Here are brief summaries of the research and progress completed by each of the two ACGT Research Fellows. This information was provided to ACGT by the scientists to illustrate the important progress they made in advancing effective cell and gene therapies for cancer.
PhD University of Pittsburgh School of Medicine
Dr. Glorioso completed his ACGT research grant in 2021. His project – “Antigenic Stealthing of oHSV for Systemic Treatment of Melanoma” – focused on one of the most common skin cancers.
Dr. Glorioso researched the use of engineered viruses –specifically, the herpes simplex virus (HSV) – to infect cancer cells and eventually break them apart. This tactic exposes proteins that were previously hidden in the cancer cells to the immune system. However, the human body is already resistant to the herpes virus, meaning the immune system would confront and likely kill the virus before it could infect the cancer cells.
This research initiative explored how to direct the immune system to “stand down” while the HSV traveled to the cancer cells. In a test on mouse models, the modified herpes virus had an impressive presence in the tumor just six days after delivery of the therapy. This result reveals a possible way to subdue the immune system so oncolytic virus therapy can effectively treat solid tumor cancers.
Daniel Powell, PhD University of Pennsylvania Perelman School of Medicine
Dr. Powell completed his ACGT research grant in 2022. His project – “Phase 1 Trial of Folate ReceptorAlpha CAR T-Cell Therapy for Solid Cancer” – focused on ovarian cancer, which is one of the most common and deadliest types of cancers for women.
Dr. Powell and his team developed CAR T cells specifically for folate receptor-alpha, which is a cancer protein found in 80–90 percent of ovarian cancer cases. The Phase 1 clinical trial is still ongoing, so complete results are not yet available but, in interim feedback, Dr. Powell reports that a few patients have responded to therapy, meaning the tumors shrank. This is promising news, and ACGT looks forward to the completion of Dr. Powell’s clinical trial.
4
Joseph Glorioso,
Our year 2 collaboration focus on glioblastoma.
2022 has seen critical progress and compelling results in cell and gene therapies for brain cancers. Among all cancer types, brain tumors are one of the toughest diseases to treat. It’s difficult for therapies to get past the brain’s natural protections to find and penetrate tumors. Effective immunotherapy treatments must be able to find and eliminate cancer cells without damaging healthy brain cells, and the side effects of the therapies themselves, like increased swelling, must also be carefully managed. New cell and gene therapies must include innovative delivery, monitoring and management strategies as well as anti-cancer effectiveness. This complexity requires collaboration to share scientific knowledge, technological innovation and exquisite patient care to succeed.
In 2022, ACGT built alliances and funded expert teams across academia to support the necessary knowledge and resource-sharing that will result in new clinical insights into brain cancers.
Our collaboration in glioblastoma (GBM) with the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute began in 2021, and we are now at the end of Year 2 of this important program.
Our collaborative efforts have allowed 562 tissue samples –from children and adults including samples of newly diagnosed and recurrent brain tumors and from patients who have received different types of therapies – to be collected and housed in a centralized database. The samples are currently being analyzed using a technology called MIBI (multiplexed ion beam imaging) that allows researchers to interpret cellular interactions. Data from other public sources are also being integrated to build a robust database that has not been available previously for brain tumor researchers.
The program is providing promising insight into what is happening within brain tumors; how immune cells like T cells, myeloid cells and macrophages interact with cancer cells; where they are within tumors; and if there are differences between interactions for newly diagnosed patients, recurrent patients, adults and children.
As ACGT moves into Year 3 of this collaboration, we look forward to achieving a new actionable understanding of the complexities of GBM and being able to ask and answer questions that were previously hidden from researchers.
5
Searching for the most impactful investments.
Advancing the cell and gene therapy pipeline through biotech investment.
The cell and gene therapy biotech pipeline has grown exponentially in the last decade with more solid tumor clinical trials and more innovative science than ever before. In 2022, ACGT has been fully engaged in building sustainable partnerships and collaborations that it believes will lead to breakthroughs in solid tumors in the near future.
ACGT Academic Research Grants fund critical pieces of the scientific puzzle that will ultimately change the lives of people living with brain cancers and other solid tumors. Academic research is the first step in building a pipeline of therapies for patients. After that, biotech companies are the critical drivers of Phase 2 and Phase 3 clinical trials. They provide larger numbers of patients, which are necessary for gaining FDA approval of new treatments. These companies are
often founded by expert scientists and funded by investors and venture capitalists.
In 2022, ACGT partnered with Chardan Capital Markets, LLC, an investment bank with specific expertise in funding and building genetic medicine companies. With the combined expertise of the ACGT Scientific Advisory Council and Chardan’s investment and business acumen, this partnership is seeking and assessing highrisk, high-reward investment opportunities in biotech companies working to develop breakthrough, curative cancer treatments. Careful investments in the most promising of these companies can be leveraged to deliver financial returns for reinvestment into other ACGT research and programs, thus creating a sustainable future for the organization.
This partnership launched a series of high-level workshops for young companies with compelling
cell and gene therapy missions. The first workshop took place in April and focused on companies tackling the tumor microenvironment. Cancer manipulates the surrounding cellular world to create the best environment for it to spread and grow. This can include controlling the expression of proteins that flag cancer cells and evading the body’s immune response in the area surrounding the tumor, effectively allowing the tumor to hide. This ability often leads to late diagnosis of diseases like pancreatic and ovarian cancers, in turn leading to poor outcomes for patients.
By understanding and controlling tumor microenvironments, biotech companies can develop new cell and gene therapies that can find, infiltrate and kill tumors. In the fall, this partnership will hold its second workshop to further build a pipeline of promising investment opportunities.
Industry Gifts. Our Alliance Partners Program.
ACGT programs are supported by our Alliance Partners, including stakeholders across cancer cell and gene therapy research and development. ACGT’s goal is to build an alliance of researchers, clinicians, companies, service providers, investors, funders and patients to advance much-needed lifesaving cancer cell and gene therapies.
In 2022, ACGT welcomed two new Alliance Partners:
6
Partner with ACGT! Get in touch with us to discuss how a company or organization can support ACGT and receive collaborative benefits. Call (203) 358-5055 or email info@acgtfoundation.org
Ways you can make a difference.
ACGT is here to help: If you have any questions, please email info@acgtfoundation.org or call (203) 358-5055.
100% of donations go toward life-saving research.
ACGT is the first and only funding agency dedicated exclusively to advancing cancer cell and gene therapy research. Since the day it was founded in 2001, 100 percent of all public donations directly support innovative frontline scientists working on thoroughly vetted and responsibly monitored strategies for cancer cell and gene therapies. A separate fund satisfies all administrative and fundraising costs.
Donate in honor or memory of someone you love.
Donate to ACGT in someone’s honor or memory to recognize them and to support ACGT’s efforts to advance cancer cell and gene therapy research and programs. The ACGT mission is simple — develop novel cell and gene therapies to transform how cancer patients are treated today and cured tomorrow.
Legacy gifts support extraordinary research today and tomorrow.
ACGT’s most dedicated champions are invited to work with the ACGT staff to design personalized legacy gifts that achieve individual financial goals while ensuring cancer cell and gene therapy advancements continue well into the future.
Members of the ACGT-Edward Netter Legacy Society enjoy peace of mind knowing their gifts are guarded and guided by scientific rigor and sound organizational stewardship. Society members
also enjoy exclusive VIP access to special events and information –from the annual ACGT Awards Gala to intimate social and educational gatherings with ACGT Research Fellows and other world-class scientific thought-leaders.
There are many ways to build legacy gifts, including qualified retirement assets, charitable bequests, life insurance, donoradvised funds and charitable beneficiary designations. 100 percent of all donations go directly to research and programs. Donors are reminded to consult qualified professional advisors on how a gift to ACGT might fit into overall plans and eligibility for tax benefits.
Workplace giving and matching gifts.
One of the easiest, most effective ways to support ACGT is through workplace giving – employersponsored programs that empower individuals to support their favorite charities through matching gifts and/or donations deducted directly from their employee paychecks. Visit the ACGT Donate webpage (https://acgtfoundation.org/donate/) to identify participating employers and/or learn how to enlist new employer participation.
For federal employees, the Combined Federal Campaign (CFC) is a workplace-giving campaign that is typically conducted annually between October and December. Participating civilian employees, military personnel, postal workers and federal retirees can designate Alliance for Cancer Gene Therapy, CFC #41537 as the recipient of their pledges.
For more information, visit https://cfcgiving.opm.gov/offerings.
Donor-advised funds maximize charitble tax deductions.
Donor-advised funds (DAFs) are simple, flexible and tax-efficient investment accounts established by individuals to benefit causes they care about (IRS-qualified public charities). A DAF can be set up with most brokerages by donating cash, securities or other assets. Gifts typically are fully tax-deductible. To designate Alliance for Cancer Gene Therapy as a beneficiary, use tax ID number is 06-1619523.
Gifts of stock and securities. Make a bigger impact by donating long-term appreciated securities, including stock, bonds and mutual funds directly to ACGT. Before-tax gifts are typically tax-deductible for the full market value. By donating stock and securities that have appreciated for more than a year, donors currently maximize their tax deductions and increase the value of their gifts by 20%.
Most banks and brokerage firms require a simple letter of instruction or authorization to transfer assets. It’s a good idea to start the process at least two weeks before December 31.
Donate cryptocurrency.*
The IRS classifies cryptocurrencies as property for tax purposes, so a donation of cryptocurrency to ACGT is tax-deductible and it is a nontaxable event, which means it does not incur capital gains tax on an appreciated amount. Learn more at thegivingblock.com/faq.
*Always consult a qualified professional advisor on how a gift to ACGT might fit into your overall plans and your eligibility for tax benefits.
7
Affiliated Events.
Event partners. Fundraising events. ACGT’s growing sphere of influence is demonstrated by the continued expansion of affiliated fundraising organizations. These allies create important opportunities for selfless individuals across the U.S. to rally in service of the ACGT mission. 100 percent of contributions from these organizations goes directly to research that advances cancer cell and gene therapies.
Swim Across America
Fairfield County 2022 marked the 16th anniversary of the Swim Across America (SAA) Fairfield County Open Water Swim benefiting ACGT. Since its inception, SAA has donated more than $5 million to ACGT to help fund ACGT Research Fellows. Current Fellows include Brian Brown, PhD (Mount Sinai), Sidi Chen, PhD (Yale Cancer Center), Stephen Gottschalk, MD (St. Jude Children’s Research Hospital), and Noriyuki Kasahara, MD, PhD (University of California, San Francisco). Past Fellows include Khalid Shah, PhD, MSc (Harvard Medical School), Thomas Kipps, MD, PhD (University of California, San Diego), Arnob Banerjee, MD, PhD (University of Maryland), John Bell, PhD (Ottawa Hospital Research Institute), Fan Yang, PhD (Stanford University), Samuel Katz, MD, PhD (Yale University School of Medicine), Crystal Mackall, MD (Stanford University), and Greg Delgoffe, PhD (University of Pittsburgh).
Visit swimacrossamerica.org.
Wendy Walk Virtual 5K
Wendy Walk is one of the few organizations dedicated to the advancement of sarcoma research. Funds raised through Wendy Walk fund the scientific research of medical professionals from across the globe who are focused on developing innovative treatments for this rare form of cancer. Since 2015, Wendy Walk has raised more than $535,000 for ACGT and has helped fund ACGT Research Fellows, including Stephen Gottschalk, MD (St. Jude Children’s Research Hospital), Crystal Mackall, MD (Stanford University), and Seth Pollack, MD (Fred Hutchinson Cancer Research Center, now at Northwestern University). Wendy Walk 2022 was held on Sunday, Sept. 18, 2022.
Visit wendywalk.org.
Play for P.I.N.K.
The fourth Innis Arden Golf Club Play for P.I.N.K. golf and tennis event will be presented by volunteers on Thursday, Sept. 29, 2022. Proceeds from raffle sales and direct donations will benefit ACGT programs that focus on pancreatic cancer in memory of committee member Bonnie Bancroft.
Visit acgtfoundation.org/InnisArden.
Leave It On The Road
Leave It On The Road (LIOTR) is an elite long-distance cycling event that raises money for cancer. Since 2020, LIOTR has designated ACGT as its beneficiary and made unrestricted donations totaling $139,000. These donations go directly to ACGT Research Fellows and research programs.
Visit leavitontheroad.org.
8
Progress in brain cancer research.
2022 has seen compelling results from brain cancer clinical trials that have their scientific roots in ACGT grant funding. Crystal Mackall, MD, of Stanford University, has been forging ahead in building a robust clinical platform to bring CAR-T therapies to patients with brain tumors that previously have had no effective treatments. Dr. Mackall’s work in CAR T has been driven by rigorous science, creative and collaborative strategies, and a tenacity to bring hope to patients with the direst prognosis.
ACGT originally funded Dr. Mackall in 2016 to develop a CAR T-cell therapy targeting a protein called GD2 for pediatric sarcoma cancers. This protein was then identified by Dr. Mackall’s colleague at Stanford University, Michele Monje, MD, PhD, as a key target in diffuse intrinsic pontine glioma (DIPG), a deadly brain tumor that primarily affects children. In 2022, the clinical team presented groundbreaking trial results in patients with DIPG at important medical meetings, inspiring and educating the research community on the power and promise of cell and gene therapies for all solid tumors.
Additional brain cancer research funded by ACGT continues to expand the pool of knowledge shared by scientists, including pre-clinical studies of oncolytic viruses for brain cancers. ACGT Research Fellow Noriyuki Kasahara, MD, PhD, at University of California, San Francisco, is studying retroviral replicating vectors (RRV). RRVs can deliver a therapeutic gene with a specific function to a cancer cell and insert it, thereby enabling cell-killing, while ACGT Research Fellow Antonio Chiocca, MD, PhD, at Brigham and Women‘s Hospital in Boston, is developing a novel GADD34-expressing oncolytic virus for use in glioblastoma trials. Both of these research programs led by ACGT Scientific Advisory Council members are built on years of expertise that will continue to lead to breakthroughs for patients. ACGT will share insights into these studies as they become available throughout the year.
ACGT Research Fellow using technology to improve cell and gene therapy.
The current process for CAR T-cell therapy involves removing some of a patient’s T cells, adding a new protein receptor to them to target cancerous proteins and reinserting the enhanced T cells back into the patient’s bloodstream. But, what if there was a quicker and easier way to strengthen the T cells without extracting them from the patient?
This is the basis of the research of Matthias Stephan, MD, PhD, an ACGT Research Fellow working at Fred Hutchinson Cancer Research Center (Seattle, WA). Specifically, Dr. Stephan is exploring whether he and his team can develop injectable mRNA nanoparticles to transform ordinary T cells into super-powered anti-cancer immune cells without having to remove them from the body. This type of cutting-edge research has the power to transform cell and gene therapy by making the process of developing, delivering and receiving therapies much simpler and quicker for researchers, doctors and patients.
The nanoparticles reprogram circulating T cells with engineered T-cell receptors, which is the basis of T-cell receptor therapy. The engineered receptors help T cells look for evidence of cancerous proteins through the major histocompatibility complex, which is a network of genes presenting evidence of disease to immune cells. The difference is that most T-cell receptor therapies in development and testing require the removal of a patient’s T cells to add the receptor. Dr. Stephan’s research involves injecting nanoparticles coated with antibodies and a vaccine that adds the receptor in-vivo, meaning inside the patient’s body.
This year, Dr. Stephan continued this ACGT-funded research and had initial success in using nanoparticle injections to engineer T cells in pre-clinical human and mouse models. Dr. Stephan reported that the injectable nanoparticles created enhanced T cells for fighting prostate cancer and leukemia. The next step in this technological advancement of cell and gene therapy is a clinical trial.
By funding groundbreaking research from scientists like Dr. Stephan, ACGT is helping to bring cell and gene therapy to thousands more cancer patients. Help ACGT gain ground, provide more grants to the top cancer centers and create life-saving cell and gene therapies by making a donation today.
9
Latest FDA approvals of cell and gene therapy linked to ACGT funding.
Five years ago in 2017, Kymriah became the first of seven cell and gene therapies approved by the U.S. Food and Drug Administration for cancer treatment. The FDA approved Kymriah for patients up to 25 years old with acute lymphoblastic leukemia. It was a landmark moment for the field of cell and gene therapy and, in particular, for Alliance for Cancer Gene Therapy.
This cell and gene therapy was developed thanks to funding from Alliance for Cancer Gene Therapy and the research of Carl June, MD, (University of Pennsylvania), an ACGT Research Fellow at the time and now a member of ACGT’s Scientific Advisory Council.
Soon after its first approval, Kymriah (brand name for tisagenlecleucel) was approved for patients with large B-cell lymphoma who have tried and failed with two other types of treatment. In 2022, Kymriah received its third approval for blood cancer: follicular lymphoma, the most common slow-growing non-Hodgkin lymphoma, a type of blood cancer affecting around 15,000 people in the United States each year. The therapy is approved for patients who have tried two other types of treatment with no long-term success in controlling the cancer.
While Kymriah was the first cell and gene therapy approved for cancer, it was far from the last. Today there are a total of seven approved therapies, including Kymriah:
• Yescarta® (axicatbagene ciloleucel), a CAR T-cell therapy originally approved in 2017 for non-Hodgkin lymphoma patients after two rounds of failed treatment, is now approved after only one round of failed treatment.
• Breyanzi® (lisocabtagene maraleucel), a CAR T-cell therapy originally approved in 2021 for non-Hodgkin lymphoma patients after two rounds of failed treatment, is now available after just one round of failed treatment.
• Abecma® (idecabtagene vicleucel), approved in 2021, is a CAR T-cell therapy for multiple myeloma after patients try at least four other rounds of treatments with no long-term success.
• Tecartus® (brexucabtagene autoleucel), approved in 2021, is a CAR T-cell therapy for mantle cell lymphoma after patients have disease progression after trying another treatment.
• Carvykti® (ciltacabtagene autoleucel), the newest FDAapproved CAR T-cell therapy, approved in 2022, is approved for multiple myeloma patients after four rounds of unsuccessful therapy.
• Kimmtrak® (tebentafusp-tebn), approved in 2022, is a T-cell receptor therapy to treat for uveal melanoma, a rare type of skin cancer in the eye. Kimmtrak is the first T-cell receptor therapy approved by the FDA for cancer.
According to the Cellular Immunotherapy Data Resource, from 2016-2021, there were 6,343 patients treated with CAR T-cell therapy. The number has increased year over year since 2016, with nearly 2,000 people receiving CAR T-cell infusions in 2021 alone. With the new approvals – and more patient awareness of these therapies –the number of cancer patients benefiting from cell and gene therapy is surely increasing.
ACGT’s ability to fund innovative research that has led to these new therapies is due largely to the generous contributions of our donors. This donor support helped Kymriah become the first cell and gene therapy approved for cancer, and Kymriah paved the way for the other therapies that have followed.
10
Effective and efficient — financial performance.
For 2022 ACGT Fiscal Year (May 1, 2021, to April 30, 2022)
Statement of activities 2022 2021 Support and revenue
Contributions $ 2,454,379 $ 1,301,524 Special events (net of direct benefits to donors of $0 and $76,010 for the years ended April 30, 2022 and 2021, respectively) 0 113,643
Contributed services 748,568 812,049 Interest and dividend income 73,459 93,859
Net realized and unrealized (losses) gains on investments (229,342) 1,482,351 Royalty income 161,669 94,566 Other income 72,144 0
Total support and revenue 3,280,877 3,897,992
Expenses
Program services: Research grants and awards 1,959,083 2,683,846 Suppor t services: Management and general 351,300 409,076 Fundraising 242,406 305,690
Total expenses 2,552,789 3,398,612 Increase (decrease) in net assets 728,088 499,380 Net assets at beginning of year 5,048,916 4,549,536 Net assets at end of year $ 5,777,004 $ 5,048,916
Statement of financial position 2022 2021 Assets
Cash and cash equivalents $ 3,060,876 $ 576,360 Investments at fair value 3,828,652 5,893,227 Contributions receivable 13,771 260,226 Other assets 115,238 121,621
Total assets $ 7,018,537 $ 6,851,434
Liabilities
Grants payable $ 1,199,610 $ 1,757,323
Accrued expenses 41,923 45,195
Total liabilities 1,241,533 1,802,518
Net assets
Without donor restrictions 3,541,227 3,697,110
With donor restrictions 2,235,777 1,351,806
Total net assets 5,777,004 $ 5,048,916
Total liabilities and net assets $ 7,018,537 $ 6,851,434
Alliance for Cancer Gene Therapy, Inc.’s complete financial statements are available upon request. Management, general and fundraising expenses are underwritten by a separate fund so that 100% of all public donations go directly to research and programs. As a 501(c)3 not-for-profit, public interest corporation, ACGT carefully manages its resources to ensure organizational stability, operational excellence and sound investments.
11
11
Thank You for being part of our alliance.
For 2022
ACGT Fiscal
Founder’s Circle ($50,000+)
Gbola Amusa, MD, MBA, CFA Chardan Capital Markets Geneve Corporation * Mrs. Barbara Netter * Swim Across America * University of Pennsylvania * The Wasily Family Foundation Wendy Walk Wilson Wolf Manufacturing Corporation
President’s Circle ($25,000+)
Mr. and Mrs. Andy Alisberg * Cogan Family Foundation * Leave It On The Road
Pathfinders ($10,000+)
Adicet Therapeutics, Inc. Teresa Burgess, PhD Clifford Chance US LLP
Mr. and Mrs. David M. Darst, Jr. * Mr. Daniel Englander Mr. and Mrs. Alan Englander * Mr. and Mrs. Bill Fitzgerald * Peter A. Glicklich, Esq. * Mr. Michael Gregory * Mr. and Mrs. Peter Hearn Mr. and Mrs. Chau Q. Khuong * Dr. and Mrs. John Lahey * The Lapin Foundation Mr. Zachary D. Miller and Mrs. Alissa B. Miller Mr. John Miller * Play for Pink and Purple Mr. and Mrs. John C. Sites, Jr. * Klaus R. Veitinger, MD, PhD Mr. and Mrs. Robert D. Weisman * Mr. and Mrs. Martin E. Winter * Wrightson Ramsing Foundation *
Year (May 1, 2021, to April 30, 2022)
Benefactors ($5,000+)
Community Health (CHC) * Mr. and Mrs. Jeb Embree * Mr. and Mrs. Bradley Goldberg Ms. Joanna Karatzas and Mr. Philip Enquist * The Kaufmann Foundation
Mrs. Mary C. Kirk * Mr. and Mrs. Robert Levis S & L Marx Foundation * Mr. Martin Oliner
Mr. and Mrs. Toby Ritter Charles S. Raizen Foundation Inc. Mr. Robert Shasha Mr. Tom Tryforos *
Patrons ($1,000+)
America‘s Charities
Mr. Steven C. Annus * Anonymous (2) Mr. Stephen Corman
Mr. Martin Dickman * Ms. Pamela Anne Duke * Mitchell H. Finer, PhD Mrs. Arline Gardner Mr. Leonard Gero Mrs. Nancy C. Gregory Drs. Sandra and Ira Harkavy Mr. and Mrs. James D. Hoffman Mrs. Alice Kaplan * Ms. Carol A. Klimek
Mr. and Mrs. Andrew Kramer * Michael T. Lotze, MD Mrs. Dorothy Walton-Luglan and Mr. Leif Luglan Stephanie Catherine Maistrellis Mr. Douglas Olson
Mr. and Mrs. Barnet Phillips * Mr. James A. Read Mr. Michael E. Reeves *
Mr. and Mrs. Ralph L. Roberson Mrs. Sandra Rogol
Mr. and Mrs. John Rosenberg Scrivan Family Foundation
Mr. and Mrs. Louis Senatore * Mr. and Mrs. Bobeck Shayegani * Mr. and Mrs. David Sherman * Mr. and Mrs. Jonathan K. Simon
Mr. and Mrs. Ronald Simon
Mr. and Mrs. H. William Smith * Mrs. Judy Soley
Ms. Nicky Cass and Mr. Henry Spencer
Mr. and Mrs. Markley Suthers * United Way of the Greater Lehigh Valley, Inc.
Advocates ($500+)
Judith Duran
Michael Englander, PhD * Mr. and Mrs. Carl Goldman
Mr. and Mrs. Sheldon Gordon * Ms. Evelyn Holtzman
Mr. and Mrs. Tom Hughes * Ms. Barbara Jo Kirshbaum Mr. Justin Klein Ms. Barbara Lavery
Ms. Wendy Lindquist Ms. Rachel Lipari Mrs. Janet Lobsenz
Mr. and Mrs. Richard Malnight * Ms. Leslie McDonald
Ms. Janet McMahon
Mr. and Mrs. James Mendler * Mr. and Mrs. David Parisier Ms. Leigh Haskell Perkins
The Perkins Charitable Foundation
Charity Clients of The Giving Block, a Donor Advised Fund of Renaissance Charitable Foundation
* Denotes Hall of Fame members who have donated for five consecutive years or longer.
12
Mr. and Mrs. Stephen Sahlein * Ms. Valerie Saiz
Dr. and Mrs. Melish Thompson Mr. and Mrs. Charles Tusa
Robert Vonderheide, MD, PhD Mr. and Mrs. Scott Welsh * Mr. and Mrs. Jordan E. Yarett
Supporters (Up to $499)
Amazon Smile
Leslie Andersen
Ms. Shelly Andrews Mr. Michael Armstrong Ms. Danielle Ayers Salina Bakshi Mr. Tomas Balino Mrs. Lucy Banker Mr. Kenneth Bartels and Ms. Jane Condon
Benevity
Mr. and Mrs. Marvin Berenblum Mrs. Lisa Brooks Bologna Mr. and Mrs. Harry Bower * Mr. Robert Brady
Stan Brosowsky
Brian Brown, PhD Ms. Connie Burnett * Mr. and Mrs. James Calabrese Mr. and Mrs. Robert Chandler * Logan Chang
Mr. George Emmanuel Christianos Mrs. Pamela Van Hoven Clark Mr. Brian Coker Mr. and Mrs. Peter Crumbine Pavan Dalal
Mr. Charles Leykum and Ms. Elizabeth Darst Tyler Davis Mr. and Mrs. Chuck Dawson
Ms. Helen R. DiGiovanni Mr. Robert Donald Ms. Victoria Dussich Mr. Eugene Eanes Sharon Ellison
Ms. Susan Mastronardi Fahey Mr. and Mrs. James Fogarty Violeta Franco
Ms. Kathryn Gabler * GE Appliances Employee Giving Campaign Mark and Jane Grein Mr. John Griswold Ms. Tracy Grossman Nan Hallock
Mr. Kevin Honeycutt Mr. and Mrs. Thomas Hughes Mr. Kenneth Irvine Mrs. Kareen Jacobs * Ms. Roberta Jahrmarkt Mr. Jim Jasper Christine Jensen Mr. H. Steven Kanofsky * Ms. Carol Kenyon Mr. Patrick La Pella * Mr. David Liu
Mr. and Mrs. James Lockhart III Mrs. Karen Loulakis Peter and Fran Lund Ms. Cornelia MacFadyen Mr. and Mrs. William Mack Mr. and Mrs. Ray Marschall Mr. Michael Martin Ms. Sheila Martin Ms. Susan Massey Mr. Allen McCoy * Mr. and Mrs. Clifford Millian Mr. Scott Mt. Joy Network for Good
Melissa and Dwight Norrgard Ms. Jennifer O‘Connell Ms. Kathryn M. Payne PayPal Giving Fund Denise and Thomas Pote * Greg Prym
Ms. Barbara L. Puszert * Mr. Brett Raphael Charles and Mariellen Rich
Mr. and Mrs. Steve Rippon * Ms. Deborah A. Rivers * Mr. and Mrs. Victor H. Romley * Mr. and Mrs. Dennis Rosenzweig * Mr. and Mrs. Richard Rupp * Ms. Jean Naomi Scandlyn Mr. and Mrs. Brian Schlier * James Shea Mr. and Mrs. Harold Simkowitz * Mr. and Mrs. Laurence Simon Ms. Kathryn Spain Mr. and Mrs. Ronald Strackbein Ms. Susan Strba
Mrs. Virginia D. Thomas Dr. Deborah and The Honorable Richard Tolchin Mr. and Mrs. Paul Toretta * Ms. Yvonne Tropp
Mr. Robert Tucker, Esq Mr. Robert A. Van Cleef Ms. Pam Van Hoven Clark John L. and Sue Ann Weinberg Foundation
Mr. and Mrs. George Whipple Mr. and Mrs. Jack Williams * Mr. and Mrs. Donald Young
ACGT makes every effort to ensure the accuracy of these lists. If your name has been omitted or misprinted, please accept our sincere apologies and contact ACGT at info@acgtfoundation.org or (203) 358-5055 so that a correction can be made
13
Board of Directors.
The ACGT Board of Directors is responsible for advancing the organization’s mission and ensuring its sustainability through sound governance, advocacy and stewardship. These influential leaders reflect the scope and diversity of the ACGT community – from world-class scientists, biotech and pharma leaders to venture capitalists, philanthropists and patient advocates.
Barbara Netter, MS
Honorary Chairman and Co-Founder
Psychotherapist
Peter A. Glicklich Chairman of the Executive Committee
Managing Partner Davies, Ward, Phillips & Vineberg LLP
Andy Alisberg Investor
Gbola Amusa, MD, MBA, CFA Partner and Chief Scientific Officer Chardan
Terri Burgess, PhD Co-Founder Paradigm Shift Therapeutics
David M. Darst, Jr. Chief Operating Officer Inspirna
Daniel Englander Managing Partner Ursula Capital Partners
Michael Gregory Co-Managing Partner Avidity Partners
Tracy B. Holton Attorney and Author
Chau Khuong Biotech Entrepreneur and Investor
John L. Lahey, PhD Past President Quinnipiac University
Alexandra Landes Founder Wendy Walk
Chen Schor, MBA, CPA President and Chief Executive Officer Adicet Bio
John C. Sites, Jr. Partner Wexford Capital, LLC
Klaus Veitinger, MD, PhD, MBA Venture Partner OrbiMed Advisors
Martin Winter Managing Director Alvarez & Marsal
Martha Zoubek Philanthropist Wrightson-Ramsing Foundation
Edward Netter
In Memoriam, Founding President (2001-2011)
14
Professional Team.
The ACGT Board of Directors and ACGT Scientific Advisory Council rely on the focused ACGT Professional Team to help advance the ACGT mission by responsibly managing the business of the organization.
Kevin Honeycutt CEO and President khoneycutt@acgtfoundation.org (203) 358-5055
Barbara Lavery Chief Program Officer blavery@acgtfoundation.org (203) 358-5055
H. William Smith Secretary and Chief Legal Counsel wsmith@ihc-geneve.com (203) 358-8000
Christine Herman Treasurer cherman@ihc-geneve.com (203) 358-8000
Devin Golden Content Manager dgolden@acgtfoundation.org (203) 358-5055
Sharon DaCosta Foundation Administrator sdacosta@acgtfoundation.org (203) 358-5055
Scientific Advisory Council.
The ACGT Scientific Advisory Council comprises the most accomplished thought leaders in the field of cancer cell and gene therapy. Their expert guidance distinguishes ACGT from other funding agencies.
Michael T. Lotze, MD Council Chair University of Pittsburgh Hillman Cancer Center
Stuart A. Aaronson, MD Icahn School of Medicine at Mount Sinai
Nduka Amankulor, MD University of Pennsylvania
John Bell, PhD Ottawa Hospital Research Institute
Christine Brown, PhD City of Hope
E. Antonio Chiocca, MD, PhD, FAANS Brigham and Women’s Hospital
Mitchell H. Finer, PhD MPM Capital
Joseph C. Glorioso, III, PhD Past Council Chair University of Pittsburgh Hillman Cancer Center
Carl H. June, MD University of Pennsylvania Abramson Cancer Center
Noriyuki Kasahara, MD, PhD University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
Crystal L. Mackall, MD Stanford University
Pamela Ohashi, PhD University of Toronto
Stephen J. Russell, MD, PhD Mayo Clinic Cancer Center
Michel Sadelain, PhD Memorial Sloan Kettering Cancer Center
George D. Yancopoulos, MD, PhD Regeneron Pharmaceuticals
Savio L.C. Woo, PhD Council Chair Emeritus Icahn School of Medicine at Mount Sinai, retired
15
Celebrating 22 years of ACGT Research Fellows.
In its 22 years of cancer cell and gene therapy research leadership, ACGT has awarded 63 grants totaling $31.5 million to 61 innovative researchers at 36 of North America’s top cancer research institutions.
Institutions listed reflect the researcher’s association at the time of the grant award.
Nabil Ahmed, MD, MPH (2011) Baylor College of Medicine, Brain Cancer
Arnob Banerjee, MD, PhD (2014) University of Maryland School of Medicine, Blood Cancer
Jeffrey S. Bartlett, PhD (2003) The Research Institute at the National Children’s Hospital, Ovarian Cancer
John Bell, PhD (2014) Ottawa Hospital Research Institute, Brain Cancer
Brian Brown, PhD (2020) Icahn School of Medicine at Mount Sinai, Solid Tumors
Roberto Cattaneo, PhD (2007) Mayo Clinic College of Medicine, Lymphoma/Leukemia
Sidi Chen, PhD (2020) Yale University School of Medicine, Pancreatic Cancer
Yvonne Chen, MS, PhD (2016) University of California, Los Angeles, Lymphoma/Leukemia
Antonio E. Chiocca, MD, PhD (2008)
Harvard Medical School, Brain Cancer
Laurence Cooper, MD, PhD (2004) University of Texas MD Anderson Cancer Center, Lymphoma/ Leukemia
George Coukos, MD, PhD (2006) University of Pennsylvania Abramson Cancer Center, Ovarian/ Peritoneal Cancer
Andrew M. Davidoff, MD (2003) St. Jude Children’s Research Hospital, Neuroblastoma
Greg Delgoffe, PhD (2017) University of Pittsburgh School of Medicine, Melanoma
Glenn Dranoff, MD (2011) Dana Farber/ Harvard Cancer Center, Leukemia
Joseph A. Fraietta, PhD (2019) University of Pennsylvania Abramson Cancer Center, Prostate Cancer
Marco Gallo, PhD (2017) University of Calgary, Brain Cancer
Joseph C. Glorioso, PhD (2018) University of Pittsburgh School of Medicine, Melanoma
Stephen Gottschalk, MD (2019) St. Jude Children’s Research Hospital, Sarcoma
Thomas S. Griffith, PhD (2003) University of Minnesota, Prostate Cancer
Brent Hanks, MD, PhD (2016) Duke University Medical Center, Melanoma
Biao He, PhD (2006) University of Georgia, Breast Cancer
Meenakshi Hegde, MD (2015) Baylor College of Medicine, Melanoma
Hui Hu, PhD (2012) University of Alabama, Ovarian Cancer
Chien-Fu Hung, PhD (2005) Johns Hopkins University School of Medicine, Ovarian Cancer
Mukesh Jain, MD, FAHA (2005) Case Western Reserve University, Metastatic Cancer
Christopher Jewell, PhD (2015) University of Maryland, College Park, Lymphatic Systems
Carl H. June, MD (2004, 2008) University of Pennsylvania Abramson Cancer Center, Lymphoma/Leukemia, Ovarian Cancer
Noriyuki Kasahara, MD, PhD (2017)
University of Miami, Glioblastoma
Samuel G. Katz, MD, PhD (2016) Yale University School of Medicine, Solid Tumors
Thomas J. Kipps, MD, PhD (2005, 2010)
University of California, San Diego Moores Cancer Center, Lymphoma/ Leukemia
16
ACGT funds research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer. Grants are competitively awarded to innovative researchers and collaborative institutions in the United States and Canada upon rigorous peer review and recommendations made by the ACGT Scientific Advisory Council.
If you would like to be added to the distribution list for ACGT Requests for Application (RFA), please email your contact information to info@acgtfoundation.org.
Timothy Lane, PhD (2004) University of California, Los Angeles, Breast Cancer
Maciej S. Lesniak, MD (2007) University of Chicago, Brain Cancer
Hyam I. Levitsky, MD (2005) Johns Hopkins University School of Medicine, Lymphoma/Leukemia
Ronald Levy, MD (2008) Stanford University, Lymphoma
Michael Z. Lin, MD, PhD (2011) Stanford University, Brain/Breast Cancer
Crystal Mackall, MD (2016) Stanford University School of Medicine, Osteosarcoma
Douglas Mahoney, PhD (2013) University of Calgary, Breast Cancer
Clodagh O’Shea, PhD (2008) Salk Institute for Biological Studies, Breast Cancer
Kah-Whye Peng, PhD (2007) Mayo Clinic Cancer Center, Multiple Myeloma
Eckhard Podack, MD, PhD (2006) University of Miami Miller School of Medicine, Lung Cancer
Seth Pollack, MD (2018) Fred Hutchinson Cancer Research Center, Sarcoma
Daniel Powell, PhD (2018) University of Pennsylvania Abramson Cancer Center, Ovarian Cancer
Suzie Pun, PhD (2005) University of Washington, Metastatic Cancer
Todd R. Reilly, PhD (2003) Johns Hopkins University, Breast Cancer
Katherine Ryman, PhD (2004) University of Pittsburgh Center for Vaccine Research, Prostate Cancer
Michel Sadelain, MD, PhD (2004) Memorial Sloan Kettering Cancer Center, Lymphoma/Leukemia
Harald Sauthoff, MD (2007) New York University, Breast/Lung Cancer
Miguel Sena-Esteves, PhD (2006) University of Massachusetts Medical School, Brain Cancer
Khalid Shah, PhD, MSc (2008) Harvard Medical School, Massachusetts General Hospital, Brain Cancer
Alexander Stegh, PhD (2013) Northwestern University, Brain Cancer
Matthias Stephan, MD (2018) Fred Hutchinson Cancer Research Center, Ovarian Cancer
Koji Tamada, MD, PhD (2006) University of Maryland, Lymphatic Systems
Steve Thorne, PhD (2009) University of Pittsburgh, Breast/ Ovarian Cancer
Robert Vonderheide, MD, DPhil (2004)
University of Pennsylvania Abramson Cancer Center, Neuroblastoma
Fan Yang, PhD (2014) Stanford University School of Medicine, Brain Cancer
Yiping Yang, MD, PhD (2005) Duke University Medical Center, Lymphoma/Leukemia
Jian Yu, PhD (2005)
University of Pittsburgh School of Medicine, Lung Cancer
Herbert J. Zeh, III, MD, FACS (2012)
University of Pittsburgh, Pancreatic Cancer
Xianzheng Zhou, MD, PhD (2006) New York Medical College, Lymphoma/Leukemia
Amer H. Zureikat, MD, FACS (2022)
University of Pittsburgh School of Medicine, Pancreatic Cancer
17
One vision — a cancer-free future.
96 Cummings Point Road, Stamford, CT 06902 acgtfoundation.org
ACGT is a 501(c)3 not-for-profit, public interest corporation. Established in 2001 by Edward and Barbara Netter to fill an important niche in the cancer research community, ACGT is the first and only funding agency to exclusively embrace a progressive vision for the notoriously underfunded discipline of cancer cell and gene therapy research.
One hundred percent of all public donations directly support frontline scientists working on thoroughly vetted and responsibly monitored cancer cell and gene therapy research.
ACGT is a Gold Seal accredited non-profit as confirmed by GuideStar and is recognized by the Better Business Bureau as a trustworthy organization.
